ITI EYES signed a memorandum of understanding (MOU) with NTL Healthcare to develop artificial intelligence (AI) solutions for diagnosing women’s cancers.


ITI EYES, NTL Healthcare Sign MOU... "Develop AI Solutions for Diagnosing Women's Cancers" View original image

According to ITI EYES on November 3, the agreement will expand its medical AI solution portfolio beyond precision cancer diagnosis to include the diagnosis of women’s cancers.


The two companies plan to work closely together in various areas, including ▲ partnering to develop and enhance an AI-based platform for women’s cancer diagnosis and related solutions; ▲ jointly planning and carrying out research and development projects that draw on their domestic and overseas sales networks and healthcare technology capabilities; ▲ forming partnerships for overseas business in the field of women’s cancers; and ▲ conducting pilot projects and commercializing AI-based precision medicine solutions.


ITI EYES is advancing its medical data integration and analysis technology through its medical AI platform, GenAI Me. It plans to apply this medical AI technology to the diagnosis of women’s cancers and strengthen its solution development capabilities.



An ITI EYES representative said, “This agreement will help us define the potential applications of medical AI technology in diagnosing women’s cancers and explore overseas business opportunities. We will continue our collaboration through joint research and development and solution validation to achieve tangible business results.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing